Sanofi Consumer [SANOFICONR] vs Marksans Pharma [MARKSANS] Detailed Stock Comparison

Sanofi Consumer

NSE
Loading...

Marksans Pharma

NSE
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: Sanofi Consumer wins in 14 metrics, Marksans Pharma wins in 5 metrics, with 0 ties. Sanofi Consumer appears stronger overall.

View Metrics Details

Vital Metrics Comparison

MetricSanofi ConsumerMarksans PharmaBetter
P/E Ratio (TTM)54.8621.35Marksans Pharma
Price-to-Book Ratio42.743.03Marksans Pharma
Debt-to-Equity Ratio11.0112.93Sanofi Consumer
PEG Ratio-17.27-0.62Sanofi Consumer
EV/EBITDA42.2615.21Marksans Pharma
Profit Margin (TTM)27.62%13.20%Sanofi Consumer
Operating Margin (TTM)30.42%12.42%Sanofi Consumer
EBITDA Margin (TTM)30.42%12.42%Sanofi Consumer
Return on Equity66.30%15.29%Sanofi Consumer
Return on Assets (TTM)41.97%11.75%Sanofi Consumer
Free Cash Flow (TTM)$4.29B$337.45MSanofi Consumer
Dividend Yield1.08%0.62%Sanofi Consumer
1-Year Return-4.79%-42.49%Sanofi Consumer
Price-to-Sales Ratio (TTM)15.172.82Marksans Pharma
Enterprise Value$108.66B$71.76BSanofi Consumer
EV/Revenue Ratio15.012.71Marksans Pharma
Gross Profit Margin (TTM)72.30%57.77%Sanofi Consumer
Revenue per Share (TTM)$314$59Sanofi Consumer
Earnings per Share (Diluted)$86.95$7.73Sanofi Consumer
Beta (Stock Volatility)N/A1.23N/A
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends

Sanofi Consumer vs Marksans Pharma Stock Performance Analysis

Loading Price Chart...

Sanofi Consumer
Marksans Pharma
Sanofi Consumer Stock Overview | Marksans Pharma Stock Overview

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Sanofi Consumer1.03%-5.13%-6.70%-12.40%-1.24%-3.25%
Marksans Pharma0.14%-2.00%-0.42%-35.52%-24.91%-45.29%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Sanofi Consumer-4.79%-3.15%-3.15%-3.15%-3.15%-3.15%
Marksans Pharma-42.49%252.74%211.24%57.76%4,066.75%553.61%

News Based Sentiment: Sanofi Consumer vs Marksans Pharma

Sanofi Consumer

News based Sentiment: MIXED

October saw Sanofi deliver mixed earnings results, with revenue exceeding expectations but EPS falling short. However, significant institutional investment and a strategic move into AI-driven clinical trials suggest a commitment to long-term growth, creating a mixed but ultimately positive narrative for investors.

View Sanofi Consumer News Sentiment Analysis

Marksans Pharma

News based Sentiment: NEGATIVE

September proved to be a difficult month for Marksans Pharma, with disappointing financial results and a significant decline in stock price overshadowing positive developments like regulatory approvals. The shift in institutional investment patterns and insider selling further contribute to a negative outlook, making this a crucial period for the company to demonstrate a turnaround strategy.

View Marksans Pharma News Sentiment Analysis

Performance & Financial Health Analysis: Sanofi Consumer vs Marksans Pharma

MetricSANOFICONRMARKSANS
Market Information
Market Cap i₹108.89B₹77.07B
Market Cap CategoryMid capMid cap
10 Day Avg. Volume i13,9641,010,590
90 Day Avg. Volume i7,1961,079,284
Last Close₹4,797.60₹166.90
52 Week Range₹4,211.55 - ₹5,894.50₹162.51 - ₹358.70
% from 52W High-18.61%-53.47%
All-Time High₹5,894.50 (Jun 30, 2025)₹358.70 (Dec 02, 2024)
% from All-Time High-18.61%-53.47%
Growth Metrics
Quarterly Revenue Growth0.34%0.05%
Quarterly Earnings Growth1.09%-0.34%
Financial Health
Profit Margin (TTM) i0.28%0.13%
Operating Margin (TTM) i0.30%0.12%
Return on Equity (TTM) i0.66%0.15%
Debt to Equity (MRQ) i11.0112.93
Cash & Liquidity
Book Value per Share (MRQ)₹111.61₹54.44
Cash per Share (MRQ)₹94.19₹15.58
Operating Cash Flow (TTM) i₹2.25B₹2.42B
Levered Free Cash Flow (TTM) i₹1.81B₹3.81B
Dividends
Last 12-Month Dividend Yield i1.08%0.62%
Last 12-Month Dividend i₹55.00₹1.40

Valuation & Enterprise Metrics Analysis: Sanofi Consumer vs Marksans Pharma

MetricSANOFICONRMARKSANS
Price Ratios
P/E Ratio (TTM) i54.8621.35
Forward P/E i39.2113.83
PEG Ratio i-17.27-0.62
Price to Sales (TTM) i15.172.82
Price to Book (MRQ) i42.743.03
Market Capitalization
Market Capitalization i₹108.89B₹77.07B
Enterprise Value i₹108.66B₹71.76B
Enterprise Value Metrics
Enterprise to Revenue i15.012.71
Enterprise to EBITDA i42.2615.21
Risk & Other Metrics
Beta iN/A1.23
Book Value per Share (MRQ) i₹111.61₹54.44

Financial Statements Comparison: Sanofi Consumer vs Marksans Pharma

Financial Metrics

Loading Financial Charts...

Revenue

EBITDA

Shareholders Equity

Operating Margin

Free Cash Flow

Long Term Debt

Profit Margin

Current Ratio

Operating Cash Flow

Income Statement (MRQ)

Metric (MRQ)SANOFICONRMARKSANS
Revenue/Sales i₹1.73B₹6.20B
Cost of Goods Sold i₹388.00M₹2.62B
Gross Profit i₹1.34B₹3.58B
Research & Development iN/AN/A
Operating Income (EBIT) i₹620.00M₹770.22M
EBITDA i₹692.00M₹1.06B
Pre-Tax Income i₹668.00M₹765.98M
Income Tax i₹168.00M₹183.96M
Net Income (Profit) i₹500.00M₹582.02M

Balance Sheet & Liquidity Metrics (MRQ)

Metric (MRQ)SANOFICONRMARKSANS
Cash & Equivalents i₹3.27B₹4.96B
Total Current Assets i₹3.92B₹22.04B
Total Current Liabilities i₹1.31B₹4.77B
Long-Term Debt i₹166.00M₹2.63B
Total Shareholders Equity i₹2.73B₹24.89B
Retained Earnings iN/A₹14.22B
Property, Plant & Equipment i₹272.00M₹185.74M

Cash Flow Statement Comparison (MRQ)

Metric (MRQ)SANOFICONRMARKSANS
Operating Cash Flow iN/AN/A
Capital Expenditures iN/AN/A
Free Cash Flow iN/AN/A
Debt Repayment iN/AN/A
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricSANOFICONRMARKSANS
Shares Short iN/AN/A
Short Ratio iN/AN/A
Short % of Float iN/AN/A
Average Daily Volume (10 Day) i13,9641,010,590
Average Daily Volume (90 Day) i7,1961,079,284
Shares Outstanding i23.03M453.16M
Float Shares i6.57M214.46M
% Held by Insiders i0.71%0.46%
% Held by Institutions i0.23%0.17%

Dividend Analysis & Yield Comparison: Sanofi Consumer vs Marksans Pharma

MetricSANOFICONRMARKSANS
Last 12-Month Dividend i₹55.00₹1.40
Last 12-Month Dividend Yield i1.08%0.62%
3-Year Avg Annual Dividend i₹18.33₹0.72
3-Year Avg Dividend Yield i1.11%0.40%
3-Year Total Dividends i₹55.00₹2.15
Ex-Dividend DateApr 17, 2025Aug 01, 2025